In a significant development concerning the ‘Coldrif’ cough syrup scandal, the Enforcement Directorate (ED) has initiated searches at multiple locations in Chennai. The agency targeted seven premises linked to Sreesan Pharma, operating under the stringent provisions of the Prevention of Money Laundering Act (PMLA). This action comes in the wake of the devastating consequences of the cough syrup, which has been responsible for the deaths of numerous children. Officials confirmed that the search operations extended to the homes of high-ranking officials from the Tamil Nadu drug control office, suggesting a wide-ranging inquiry.
The ED’s move is a direct response to the unfolding tragedy in Madhya Pradesh, where the consumption of ‘Coldrif’ cough syrup resulted in the deaths of at least 22 children in the Chhindwara district. This investigation into Sreesan Pharma represents the latest in a series of ED actions against Chennai-based pharmaceutical companies. Recent actions include probes into Arvind Remedies Ltd. for a substantial bank loan fraud and an international narcotics network case involving Jaffer Sadiq. The agency is focused on tracing the financial trail and any proceeds of crime generated from the alleged illegal manufacturing and distribution of the substandard cough syrup. The objective is to dismantle any financial structures supporting such dangerous activities and hold all culpable parties accountable for the loss of innocent lives.